Maintenance therapy for AML: are we there yet?-Reference-Cited by-同舟云学术

Maintenance therapy for AML: are we there yet?

Published:2019-03-28 Issue:13 Volume:133 Page:1390-1392
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Wei Andrew H.¹^ORCID

Affiliation:

1. The Alfred Hospital; Monash University

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/133/13/1390/1556992/blood897579.pdf

Reference10 articles.

1. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients;Huls;Blood,2019

2. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system;Röllig;J Clin Oncol,2011

3. Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials;Rashidi;Blood,2016

4. Addition of androgens improves survival in elderly patients with acute myeloid leukemia: a GOELAMS study;Pigneux;J Clin Oncol,2017

5. Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre Sormain trial [abstract];Burchert,2018

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001;HemaSphere;2023-11

2. Indirect treatment comparison of oral versus injectable azacitidine as maintenance therapy for acute myeloid leukemia;Future Oncology;2022-12

3. Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy;Future Oncology;2022-10

4. Hypomethylating Agents as Maintenance Therapy in the Treatment of Elderly Acute Myeloid Leukemia:A Meta-Analysis;SSRN Electronic Journal;2022

5. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial;Journal of Hematology & Oncology;2021-08-28